Pharming Group N.V.
PHAR
$13.16
-$0.16-1.19%
NASDAQ
| 06/30/2025 | 12/31/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | 277.56M | 258.36M | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | 277.56M | 258.36M | |
| Cost of Revenue | -- | -- | 31.78M | 29.52M | |
| Gross Profit | -- | -- | 245.78M | 228.84M | |
| SG&A Expenses | -- | -- | 187.17M | 183.51M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | 19.18M | 19.24M | |
| Total Operating Expenses | -- | -- | 310.38M | 303.84M | |
| Operating Income | -- | -- | -32.82M | -45.48M | |
| Income Before Tax | -- | -- | -15.41M | -11.96M | |
| Income Tax Expenses | -- | -- | -2.08M | -1.17M | |
| Earnings from Continuing Operations | -- | -- | -13.33 | -10.79 | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | -13.33M | -10.79M | |
| EBIT | -- | -- | -32.82M | -45.48M | |
| EBITDA | -- | -- | -14.49M | -27.75M | |
| EPS Basic | -- | -- | -0.02 | -0.02 | |
| Normalized Basic EPS | -- | -- | -0.02 | -0.03 | |
| EPS Diluted | -- | -- | -0.02 | -0.02 | |
| Normalized Diluted EPS | -- | -- | -0.02 | -0.03 | |
| Average Basic Shares Outstanding | -- | -- | 2.71B | 2.69B | |
| Average Diluted Shares Outstanding | -- | -- | 2.71B | 2.69B | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |